Tuesday, 27 October 2026
Pharmacy prescribing expands to all women, PBAC backs triple-therapy inhaler, Mental health centres face workforce gaps
- 01
Federal pharmacy prescribing pilot expands to all women
Following last month’s coverage of Tasmania’s pharmacist UTI service, the Federal Government has expanded its planned 12-month pharmacy prescribing pilot from concession card holders to all women. From January, about 900,000 women will be able to obtain treatment for uncomplicated UTIs and initiation or re-supply of hormonal contraception without seeing a GP, subject to state or territory rules. RACGP President Dr Michael Wright expressed concern that the expansion was announced before the pilot had been evaluated. Women’s health expert Professor Danielle Mazza also questioned the evidence for pharmacy-initiated contraception and warned that pharmacy access could affect uptake of long-acting reversible contraception. Federal Health and Ageing Minister Mark Butler said the change would give women more choice and control, while the Pharmacy Guild said it would improve access to primary healthcare.
via RACGP newsGP
- 02
PBAC backs triple-therapy inhaler in mixed prevention decisions
A new triple-therapy inhaler has received PBAC backing, while the committee delivered mixed decisions on RSV prevention for infants and older Australians. The source does not identify the products or provide further details of the decisions, and gives limited information about their implications for PBS access.
- 03
Medical workforce gaps limit Medicare Mental Health Centre consistency
Fewer than 1% of staff at Medicare Mental Health Centres worked in medical or physical health roles, a government-commissioned national review found. Consumers, most commonly presenting with moderate or severe psychological distress, rated their mental health an average of 3.5 out of 10 before using the service and 6.9 afterwards. Workforce shortages limited access and consistency, including short waits and after-hours care, with rural and smaller centres particularly exposed. The review also found that the lack of a shared governance framework hindered cross-network learning, quality improvement and efficient service planning. It called for centralised support, national guidance on service roles, and better financial and workforce reporting across the centres and associated phone service.
- 04
Burnout gender gap widens among Australian GPs
Burnout affected 65% of female GP respondents in the past year compared with 53% of male respondents, widening the gender gap in the RACGP’s 2026 Health of the Nation survey. The survey of more than 2700 GPs also found female GPs were less satisfied with their jobs than male GPs for the first time, at 75% versus 78%. Female GPs more often reported psychological issues among the main reasons for presentations and spent more than 21 minutes with each patient on average, compared with just under 18 minutes for male GPs. A draft MBS Review Advisory Committee report found the fee structure incentivised shorter consultations and disadvantaged patients requiring, and practitioners providing, longer consultations. RACGP Vice President Dr Ramya Raman argued that Medicare needed to better recognise time and complexity, particularly for female GPs.
via RACGP newsGP
- 05
GLP-1 medicines linked to higher alopecia risk in diabetes
Adults with type 2 diabetes who started GLP-1 receptor agonists had a significantly higher risk of alopecia than those starting other glucose-lowering medicines. The BMJ study found a 37% higher relative risk compared with SGLT-2 inhibitors and a 68% higher risk compared with DPP-4 inhibitors, although the absolute risk remained low. The observational target trial emulation could not establish whether GLP-1 medicines directly caused the hair loss. Rapid weight loss and inadequate protein or iron intake may contribute to telogen effluvium, while Australian dermatologist Professor Rod Sinclair argues that shedding could potentially trigger androgenetic alopecia in susceptible patients. Whether GLP-1-associated hair loss is entirely reversible or can lead to progressive hair loss remains unresolved.
- 06
Trastuzumab pamirtecan shows modest benefit and lung toxicity
Trastuzumab pamirtecan delayed tumour progression in a phase 3 trial involving people with HER2-low breast cancer, meeting the study’s primary goal. However, BioNTech and DualityBio described the improvement as modest and reported higher rates of interstitial lung disease than in earlier testing, including severe and fatal events in a small proportion of patients. The trial had not run long enough to establish a clear survival benefit. The companies said the findings suggested the treatment’s potential benefit would be limited in the current HER2-low metastatic breast cancer treatment landscape and will discuss the data before determining next steps.
via BioPharma Dive
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.